Stay updated on MRD-Guided Treatment in NPM1mut AML Clinical Trial
Sign up to get notified when there's something new on the MRD-Guided Treatment in NPM1mut AML Clinical Trial page.

Latest updates to the MRD-Guided Treatment in NPM1mut AML Clinical Trial page
- Check4 days agoChange DetectedThe page changes from a 403 error to the ClinicalTrials.gov record for the PEMAZA study of pembrolizumab and azacitidine in NPM1-mutated AML, with its study details and status displayed.SummaryDifference51%

- Check11 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0 on the page displaying a 403 Forbidden error.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA site-wide NIH announcement about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the page. The site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check39 days agoChange DetectedThe site footer revision label changes from v3.7.0 to v3.7.1. The page continues to show a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check46 days agoChange DetectedNo changes were reported. The page context indicates a 403 access error when attempting to view the study record.SummaryDifference0.2%

- Check53 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the previous study record content with a generic error page. This change blocks access to the trial details, locations, and related information that users expect to find on the page.SummaryDifference18%

Stay in the know with updates to MRD-Guided Treatment in NPM1mut AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MRD-Guided Treatment in NPM1mut AML Clinical Trial page.